NEO INVESTOR ALERT

First and Only NeoGenomics Class Action Filed by Gibbs Law Group - Seite 2

These disclosures caused the value of NeoGenomics stock to decline dramatically, resulting in significant harm to investors.

Since the lawsuit was filed, NeoGenomics subsidiary Inivata was also sued on December 21, 2022, for alleged patent infringement by genetic testing company Natera. NeoGenomics shares dropped 7% as a result, causing further harm to investors.

About the NeoGenomics Class Action Lawsuit

The lawsuit, captioned Goldenberg v. NeoGenomics, Inc., No. 1:22-cv-10314, was filed in the U.S. District Court for the Southern District of New York and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. If you suffered a loss in NeoGenomics, you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any potential future recovery does not require that you serve as a lead plaintiff.

What Should NeoGenomics Investors Do?

To join the class action or discuss your legal rights in the NeoGenomics class action lawsuit, visit our website or contact our securities team directly at 510-876-9368.

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over two billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005941/en/

The Neogenomics Stock at the time of publication of the news with a fall of -6,10 % to 11,09USD on Nasdaq stock exchange (19. Januar 2023, 23:20 Uhr).